ResearchRadiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma
ResearchZinc availability in the tumor microenvironment dictates anti-PD1 response in tumors via increased macrophage phagocytosis
ResearchThere and back again: PD-L1 Positivity as a Biomarker for Immune Checkpoint Blockade in Urothelial Carcinoma
ResearchPhase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma
ResearchCombined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B
ResearchCombined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
ResearchExercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy
ResearchIntratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study
ResearchClinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
ResearchA phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results
ResearchClinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
ResearchPhase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)
ResearchLead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma